Biotechnology
Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid hormone receptor β (THRβ) agonist drug candidate for non-alcoholic steatohepatitis (NASH). ASC41 Phase II clinical trial is currently the most advanced 52-week Phase II clinical trial which is in...
2022-10-05 08:10
2605
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...
2022-10-04 19:00
1422
Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry
OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...
2022-10-04 14:00
1142
Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)
Phase 1 supporting data indicated an encouraging profile and confirmed the dual mechanism of action achieved through targeting both the alternative and terminal complement pathways CAMBRIDGE, Mass., Oct. 3, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering tran...
2022-10-03 19:00
1810
DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Debiopharm awards the winning scientists for the JCA (Japanese Cancer
Association) Award for innovative, disruptive, and translational oncology
research
LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2022-10-03 15:00
1597
YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
* Transaction values YS Biopharma at pre-money equity value of $834 million * Certain investors ("Forward Purchase Investors") are expected to invest $30 million in a private placement concurrently with the closing of the business combination transaction pursuant to certain forward purchase ag...
2022-09-30 04:01
2678
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
* Two distinctive platforms will streamline the antibody development process. * With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies. * DEVELOPICK™ provides early insight and selection guidance to save time and cost to maxi...
2022-09-29 19:00
1326
NeuShen Therapeutics Closes Pre-A Financing with ~$20M
* Closure of pre-A financing round led by LAMPAM Capital * Dual internal discovery platforms of small molecule and AAV-based gene therapy targeting neurological and psychiatric disorders SHANGHAI, Sept. 29, 2022 /PRNewswire/ -- NeuShen Therapeutics, Inc., a biotechnology company focusing on d...
2022-09-29 17:50
1767
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC
SUZHOU, China, Sept. 29, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide (used to be ...
2022-09-29 14:22
1352
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
WORCESTER, Mass., Sept. 29, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony, in partnership with the Worcester Business Development Corporation (WBDC), to mark the completion of...
2022-09-29 10:41
1601
Green Mountain Biotech and Kamedis Announce First Patent in China for Unique Herb-Based Acne and Skin Relief Solution
Clinically-tested solution, based on a proprietary blend of six herbs used in
Traditional Chinese Medicine, helps relieve symptoms of acne and other skin
inflammation conditions.
TEL AVIV, Israel, Sept. 29, 2022 /PRNewswire/ -- Green Mountain Biotech
2022-09-29 09:00
1479
GC Labs becomes the first Korean laboratory to obtain certification of CDC standardization programs (VDSCP & HoSt)
YONGIN, South Korea and AUSTIN, Texas, Sept. 28, 2022 /PRNewswire/ -- GC Labs, a leadingSouth Korea clinical laboratory, today announced that it has recently obtained certification of standardization programs from the U.S. Centers for Disease Control and Prevention (CDC) for vitamin D and hormone...
2022-09-29 08:17
1200
First-Ever Spinal Surgical Hand-held Robot by Point Robotics MedTech to Make Its Worldwide Debut in the United States
TAIPEI, Sept. 28, 2022 /PRNewswire/ -- Point Robotics MedTech Inc. (Point Robotics), a rising star in the field of orthopedic surgery, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its minimally invasive surgical robot, POINT™ Kinguide Robotic-Assisted Surgical Sy...
2022-09-28 21:01
1004
ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world
* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve survival for patients with ES-SCLC. * In ASTRUM-005, serplulimab combined with chemotherapy achieved by far the longest OS in first-line immunotherapy for ES-SCLC. Compared with chemotherapy, the...
2022-09-28 21:00
2144
ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY FOR ISB 1442
First patient dosed with novel biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today anno...
2022-09-28 20:30
1305
Advanced Instruments Introduces Solentim VIPS™ PRO, A High Efficiency Single Cell Seeder to Optimize Cell Line Development Workflows
VIPS PRO delivers powerful and efficient seeding technology and definitive proof of monoclonality for workflow productivity and confidence. NORWOOD, Mass., Sept. 28, 2022 /PRNewswire/ -- Advanced Instruments today announced the launch ofSolentim VIPS PRO, a high efficiency single cell seeder, at...
2022-09-28 20:05
2076
Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
* Rising from last year's ranking, the company's united effort and dedication to integrating sustainable practices in all areas of its business drew recognition from EcoVadis, which provided high marks in responsible procurement and environmental management. * More than 100,000 companies from...
2022-09-28 19:00
1334
Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfolio companies progressed greatly. ABM Therapeutics Annou...
2022-09-28 18:31
1785
The 6th China (Shenzhen) Innovation & Entrepreneurship International Competition Eindhoven, Netherlands Division is Open for Registration
DIGITAL ACCESS TO THE WORLD CREATES A BETTER FUTURE EINDHOVEN, Netherlands, Sept. 28, 2022 /PRNewswire/ -- China （Shenzhen）Innovation and Entrepreneurship Competition, known as the "Olympics" of innovation and entrepreneurship circle, is here again! The sixth International competition was offici...
2022-09-28 17:55
1273
Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost
SINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment. Located in Solaris @ Tai Seng, this 1,300 square metres faci...
2022-09-28 17:34
4693
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 298 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 294 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 278 media titles]
2024-11-25 10:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9306
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
9289
